Cogent Biosciences, Inc. beat EPS estimates 44% of the time across 16 reported quarters (7 beats, 9 misses), averaging -7.7% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.55 | $-0.52 | +5.5% | Beat | |
| Q1 FY26 | $-0.53 | $-0.53 | +0.0% | Beat | |
| Q3 FY25 | $-0.54 | $-0.50 | +7.4% | Beat | |
| Q2 FY25 | $-0.55 | $-0.53 | +3.6% | Beat | |
| Q1 FY25 | $-0.56 | $-0.52 | +7.1% | Beat | |
| Q4 FY24 | not reported | $-0.09 | not reported | not reported | |
| Q3 FY24 | $-0.55 | $-0.64 | -16.4% | Miss | |
| Q2 FY24 | $-0.55 | $-0.59 | -7.3% | Miss | |
| Q1 FY24 | $-0.50 | $-0.62 | -24.0% | Miss | |
| Q4 FY23 | $-0.54 | $-0.63 | -16.7% | Miss | |
| Q3 FY23 | $-0.50 | $-0.64 | -28.0% | Miss | |
| Q2 FY23 | $-0.53 | $-0.59 | -11.3% | Miss |
Back to COGT overview · COGT holders · COGT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.